We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Concussive Injuries Diagnosed by Measuring a Brain Protein in Blood

By LabMedica International staff writers
Posted on 02 Sep 2019
A simple blood test detects brain injury by measuring the levels of two brain proteins, which are released into the circulation following head trauma.

Elevated levels of both proteins are found in patients with nonconcussive head trauma, potentially signaling a subconcussive brain injury. More...
To formalize a clinical role for these biomarkers, investigators at Orlando Health (FL, USA) evaluated the diagnostic accuracy of the serum glial and neuronal serum biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase (UCH-L1). Levels of these proteins were determined both individually and in combination for their efficacy in detecting the presence of a concussion and for grading potential subconcussive and non-concussive brain injury in pediatric and adult trauma patients.

For the current study, blood samples were obtained from pediatric and adult trauma patients of all ages presenting with normal mental status within four hours of injury. Of 3462 trauma patients screened, 751 were enrolled for the study and 712 had relevant biomarker data. Repeated blood sampling was conducted at regular periods from four to 180 hours postinjury in adults.

For detection of concussion and gradients of injury in children versus adults, the investigators compared three groups of patients: (1) those with concussion; (2) those with head trauma without overt signs of concussion (non-concussive head trauma controls) and (3) those with peripheral (body) trauma without head trauma or concussion (non-concussive body trauma controls). A total of 1904 samples from 712 trauma patients were analyzed.

Results revealed that within four hours of injury, there were incremental increases in levels of both GFAP and UCH-L1 from non-concussive body trauma (lowest), to mild elevations in non-concussive head trauma, to highest levels in patients with concussion. In concussion patients, GFAP concentrations were significantly higher compared with body trauma controls and with head trauma controls in both children and adults. However, for UCH-L1, there were no significant differences between concussion patients and head trauma controls and between body trauma and head trauma controls in children.

The outcome of the study confirmed that GFAP outperformed UCH-L1 in detecting concussion in both children and adults. Blood levels of GFAP and UCH-L1 showed incremental elevations across three injury groups: from non-concussive body trauma, to non-concussive head trauma, to concussion. However, UCH-L1 was expressed at much higher levels than GFAP in those with non-concussive trauma, particularly in children.

"It is estimated that up to 3.8 million concussions occur in the U.S. annually from organized and recreational sports - and there are more than two million ER visits for traumatic brain injuries and concussions," said senior author Dr. Linda Papa, specialist in emergency medicine at Orlando Health. "It is a significant health problem in both athletes and non-athletes. This study includes an array of patients with different injury mechanisms, including car crashes, falls, and bicycle accidents in addition to recreational and sports injuries. It is not limited to just one group of injury types. A unique feature of this study is that it includes patients who hit their heads but have no symptoms. This group is rarely - if ever - included in biomarker studies."

The study was published in the August 25, 2019, online edition of the journal BMJ Paediatrics Open.

Related Links:
Orlando Health


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated PCR Setup
ESTREAM
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.